
Quarterly ResultAug 11, 2026, 04:14 PM
Revvity Q2 Revenue $729.7M, EPS $0.47; Acquires ACD/Labs
AI Summary
Revvity, Inc. reported mixed financial results for the second quarter and first half of fiscal year 2026. While total revenue saw modest increases, net income experienced a slight decline. The company completed the acquisition of ACD/Labs for $72.0 million and repaid €500.0 million in senior unsecured notes, demonstrating active capital management. Restructuring efforts, including workforce reductions, led to increased costs during the period.
Key Highlights
- Acquired Advanced Chemistry Development Inc. (ACD/Labs) for $72.0 million cash, plus up to $8.0 million in contingent consideration.
- Total revenue increased 1.3% to $729.7 million for the three months ended July 5, 2026, and 4.0% to $1.44 billion for the six months.
- Net income decreased 3.9% to $51.8 million for the three months ended July 5, 2026, and 3.8% to $92.5 million for the six months.
- Diluted earnings per share (EPS) rose 2.2% to $0.47 for the three months and 1.2% to $0.82 for the six months.
- Repaid €500.0 million ($571.2 million) of 2026 Notes upon maturity in July 2026.
- Repurchased $86.9 million of common stock in the first six months of 2026, with $792.7 million remaining under the program.
- Net cash provided by operating activities increased 17.0% to $307.2 million for the six months ended July 5, 2026.
- Restructuring costs increased to $46.2 million in the first six months of 2026, affecting approximately 5% of the workforce.
Price Impact
More from RVTY